NCT06601465

COgnitioN With VERiciGuat Evaluation in Heart Failure

CONVERGE-HF: COgnitioN With VERiciGuat Evaluation in Heart Failure

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: University of Alberta · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.

Detailed description

CONVERGE-HF is a randomized, open label, phase IIb trial evaluating the effect of sGC stimulator, Vericiguat versus standard of care on imaging markers and blood markers of cerebral and coronary small vessel diseases, function status, cognitive status, quality of life and clinical events in patients with heart failure and mild-to-moderate cognitive impairment. Patients will be randomized and allocated to either vericiguat or standard of care, for 26 weeks including the greater than 4 weeks timeframe for the uptitrations to the target dose.

Conditions

• Heart Failure
• Cognitive Impairment

Interventions

Type	Name	Description
DRUG	Vericiguat	Tablet - 2.5 mg, 5 mg, 10 mg

Timeline

• Start date: 2025-06-03
• Primary completion: 2026-07-01
• Completion: 2027-05-01
• First posted: 2024-09-19
• Last updated: 2025-07-31

Locations

4 sites across 1 country: Canada